JP2022507454A5 - - Google Patents

Info

Publication number
JP2022507454A5
JP2022507454A5 JP2021526394A JP2021526394A JP2022507454A5 JP 2022507454 A5 JP2022507454 A5 JP 2022507454A5 JP 2021526394 A JP2021526394 A JP 2021526394A JP 2021526394 A JP2021526394 A JP 2021526394A JP 2022507454 A5 JP2022507454 A5 JP 2022507454A5
Authority
JP
Japan
Prior art keywords
fusosome
cns
cells
target cell
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507454A (ja
JP7676305B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061424 external-priority patent/WO2020102499A2/en
Publication of JP2022507454A publication Critical patent/JP2022507454A/ja
Publication of JP2022507454A5 publication Critical patent/JP2022507454A5/ja
Priority to JP2025075701A priority Critical patent/JP2025111747A/ja
Application granted granted Critical
Publication of JP7676305B2 publication Critical patent/JP7676305B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526394A 2018-11-14 2019-11-14 Ｃｎｓ送達のためのフソソーム組成物 Active JP7676305B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025075701A JP2025111747A (ja) 2018-11-14 2025-04-30 Ｃｎｓ送達のためのフソソーム組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862767358P 2018-11-14 2018-11-14
US62/767,358 2018-11-14
US201962900064P 2019-09-13 2019-09-13
US62/900,064 2019-09-13
PCT/US2019/061424 WO2020102499A2 (en) 2018-11-14 2019-11-14 Fusosome compositions for cns delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025075701A Division JP2025111747A (ja) 2018-11-14 2025-04-30 Ｃｎｓ送達のためのフソソーム組成物

Publications (3)

Publication Number Publication Date
JP2022507454A JP2022507454A (ja) 2022-01-18
JP2022507454A5 true JP2022507454A5 (https=) 2022-11-22
JP7676305B2 JP7676305B2 (ja) 2025-05-14

Family

ID=68808599

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526394A Active JP7676305B2 (ja) 2018-11-14 2019-11-14 Ｃｎｓ送達のためのフソソーム組成物
JP2025075701A Pending JP2025111747A (ja) 2018-11-14 2025-04-30 Ｃｎｓ送達のためのフソソーム組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025075701A Pending JP2025111747A (ja) 2018-11-14 2025-04-30 Ｃｎｓ送達のためのフソソーム組成物

Country Status (10)

Country Link
US (1) US20220008557A1 (https=)
EP (1) EP3880179A2 (https=)
JP (2) JP7676305B2 (https=)
KR (1) KR20210133948A (https=)
CN (1) CN113613633A (https=)
AU (1) AU2019378881A1 (https=)
CA (1) CA3120082A1 (https=)
IL (1) IL283179A (https=)
SG (1) SG11202105079QA (https=)
WO (1) WO2020102499A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
WO2018201160A1 (en) 2017-04-28 2018-11-01 Agrospheres, Inc. Compositions and methods for enzyme immobilization
EP3615659A4 (en) 2017-04-28 2021-01-06 Agrospheres, Inc. COMPOSITIONS AND METHODS OF ENCAPSULATION AND SCALABLE DELIVERY OF AGROCHEMICALS
CA3073449A1 (en) 2017-09-25 2019-03-28 Agrospheres, Inc. Compositions and methods for scalable production and delivery of biologicals
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
CN113631718A (zh) 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3152525A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
CA3178308A1 (en) * 2020-03-31 2021-10-07 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
MX2023008081A (es) 2021-01-11 2023-09-12 Sana Biotechnology Inc Uso de vectores virales dirigidos a cd8.
KR20240028975A (ko) 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물
JP2024521811A (ja) 2021-05-28 2024-06-04 サナ バイオテクノロジー，インコーポレイテッド 短縮型ヒヒ内在性レトロウイルス（ＢａＥＶ）エンベロープ糖タンパク質を含む脂質粒子、ならびに関連する方法及び使用
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024073093A2 (en) * 2022-09-30 2024-04-04 Vesigen, Inc. Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
EP4698666A1 (en) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
EP4716750A1 (en) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
JPH10501403A (ja) * 1994-03-04 1998-02-10 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 抗体−エンベロープ融合タンパク質および野生型エンベロープ融合タンパク質を含むレトロウィルスベクターを用いる細胞型特異的遺伝子移入
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
NZ333334A (en) * 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
JP2003532368A (ja) * 1998-02-09 2003-11-05 ジェンザイム・コーポレイション 核酸デリバリービヒクル
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
JP2003533184A (ja) * 2000-03-30 2003-11-11 オックスフォード バイオメディカ（ユーケイ）リミテッド レチノイン酸レセプターβ２、そのアンタゴニスト、および神経障害治療用の遺伝子治療ベクター
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
JP2005507927A (ja) * 2001-10-30 2005-03-24 バイオジェン・アイデック・エムエイ・インコーポレイテッド パーキンソン病を処置するための方法および組成物
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
EP2339010B1 (en) * 2002-05-01 2017-04-12 Miltenyi Biotec Technology, Inc. Lentiviral vector particles resistant to complement inactivation
ATE360683T1 (de) 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
WO2004045582A1 (en) 2002-11-21 2004-06-03 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
AU2005306801B2 (en) 2004-11-08 2012-05-17 The Regents Of The University Of Colorado Structure-based compound design involving riboswitches
CN101065488A (zh) * 2005-01-20 2007-10-31 新加坡科技研究局 将核酸递送到外周神经元的方法
CA2609142C (en) * 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
WO2008071959A1 (en) * 2006-12-12 2008-06-19 Oxford Biomedica (Uk) Limited Lentiviral vectors comprising micrornas
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
WO2010053489A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
US9050269B2 (en) * 2009-03-10 2015-06-09 The Trustees Of The University Of Pennsylvania Protection of virus particles from phagocytosis by expression of CD47
EP2498823B1 (en) * 2009-11-13 2018-08-29 INSERM - Institut National de la Santé et de la Recherche Médicale Direct protein delivery with engineered microvesicles
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
KR20150029756A (ko) * 2011-06-10 2015-03-18 블루버드 바이오, 인코포레이티드. 부신백질이영양증 및 부신척수신경병증을 위한 유전자 요법 벡터
JP2013034401A (ja) * 2011-08-04 2013-02-21 Gunma Univ アストロサイトで遺伝子を発現させるためのベクター
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
GB201412494D0 (en) * 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
US10441601B2 (en) * 2015-06-30 2019-10-15 St. Jude Children's Research Hospital, Inc. Method for treating schizophrenia
JP7097070B2 (ja) * 2015-10-01 2022-07-07 ゴレイニ インコーポレイテッド クロライドチャネルの標的発現及びその使用方法
EP3365453A2 (en) * 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
US20170112773A1 (en) 2015-10-23 2017-04-27 Board Of Regents, The University Of Texas System Plasma membrane vesicles comprising functional transmembrane proteins
SG11201802408RA (en) * 2015-11-05 2018-05-30 Bamboo Therapeutics Inc Modified friedreich ataxia genes and vectors for gene therapy
US11185555B2 (en) * 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
EP3235908A1 (en) * 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
CA3030003A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
MA45783A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication
CA3078096A1 (en) * 2017-10-20 2018-10-19 Genethon Use of syncytin for targeting drug and gene delivery to regenerating muscle tissue
CN112312918A (zh) * 2018-04-18 2021-02-02 奥依信生物技术公司 促融合脂质纳米粒和制备其的方法以及其用于靶细胞特异性产生治疗蛋白和治疗与靶细胞有关的疾病、病况或障碍的用途
GB201807945D0 (en) * 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production

Similar Documents

Publication Publication Date Title
JP2022507454A5 (https=)
JP2025111747A5 (https=)
US20240141381A1 (en) Compositions and methods for treating phenylketonuria
JP6634073B2 (ja) リソソーム蓄積症処置用のアデノ随伴ウイルスベクター
JP7838779B2 (ja) フェニルケトン尿症を処置するための、プロモーターとエンハンサーの組み合わせを有するベクター
US10323073B2 (en) CRISPR-based methods and products for increasing frataxin levels and uses thereof
JP6850736B2 (ja) ムコ多糖症治療用のアデノ随伴ウイルスベクター
US20230383270A1 (en) Crispr/cas-based base editing composition for restoring dystrophin function
IL282053B (en) Recombinant glut1 adeno-associated viral vector constructs , compositions and kits comprising the same and use thereof
CN117126829A (zh) 基因构建体、表达载体、药物组合物及其用途
WO2017109039A1 (en) Endothelium-specific nucleic acid regulatory elements and methods and use thereof
Yang et al. Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46−/− mice
US20250243496A1 (en) Vector for generating a circular rna
US20210332368A1 (en) Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
US20240000914A1 (en) Chicken anemia virus (cav)-based vectors
US20250270547A1 (en) Trans-splicing ribozyme specific to apoe4 rna and use thereof
BR112021003469A2 (pt) genes sintéticos de feedback ativado, cassetes de seed match alvo e seus usos
KR20230123925A (ko) Neurod1 및 dlx2 벡터
KR20230003569A (ko) Cdkl5 결핍 장애 (cdd)의 치료에 유용한 조성물
CN117018231B (zh) 用于治疗神经病变的基因疗法及其应用
US20190111071A1 (en) Method for promoting muscle regeneration
US20240301408A1 (en) Microrna 195 compositions and methods for treating cognitive impairment
KR102315736B1 (ko) Apoe4 rna 특이적 트랜스-스플라이싱 리보자임 및 이의 용도
US20240156873A1 (en) Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins
WO2024036343A2 (en) Synergistic nucleic acid based therapeutics and methods of use for treating genetic disorders